8 April 2021 - Ajovy now offers patients greater flexibility with two dosing options available in both an auto-injector and a pre-filled syringe.

Teva Canada today announced the launch and availability of a new auto-injector for Ajovy (fremanezumab). Ajovy is a subcutaneous injection for the preventive treatment of migraine in adults who have at least four migraine days per month. When launched in 2020, Ajovy was available in a pre-filled syringe only. The product is now available in two latex-free formats: a new auto-injector and a pre-filled syringe.

Read Teva Canada press release